Welcome to our dedicated page for Alkermes news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes stock.
Alkermes plc develops and commercializes neuroscience medicines, with proprietary commercial products used in alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Company news commonly covers quarterly financial results, full-year expectations, commercial execution and presentations at healthcare and CNS investor conferences.
Clinical and medical updates focus on the company’s sleep-wake and psychiatric portfolio, including LYBALVI in schizophrenia and bipolar I disorder and alixorexton, an investigational oral selective orexin 2 receptor agonist in development for narcolepsy and idiopathic hypersomnia. Other updates include peer-reviewed data publications, research award programs and corporate developments tied to Alkermes’ biopharmaceutical operations.
Alkermes (Nasdaq: ALKS) will host a conference call and webcast at 8:00 a.m. ET (1:00 p.m. BST) on July 28, 2026 to discuss its second quarter financial results. U.S. participants can dial +1 877 407 2988 and international callers +1 201 389 0923. The webcast player and slides will be available in the Investors section of Alkermes’ website.
According to Alkermes, a replay of the webcast will be accessible about two hours after the event via the company’s website. The company describes itself as a global biopharmaceutical business focused on neuroscience, with commercial products and clinical candidates for multiple psychiatric and neurological conditions.
Alkermes (Nasdaq: ALKS) reported interim results from an ongoing long-term extension study of alixorexton, an oral selective orexin 2 receptor agonist, in adults with narcolepsy type 1 (NT1) and type 2 (NT2). At week 24, roughly nine months after first dosing in the phase 2 parent trials, all NT1 dose groups achieved normative wakefulness on the Maintenance of Wakefulness Test, with mean sleep latency around 29 minutes, and Epworth Sleepiness Scale scores in the normal range.
In NT2, mean sleep latency reached about 18 minutes, and mean ESS was 8.9 at week 24 across participants. NT1 median weekly cataplexy rate declined versus baseline. Patient-reported cognition and fatigue shifted from moderate impairment at baseline to normal or mild ranges. No serious treatment-emergent adverse events were reported; common events included headache, urinary symptoms, insomnia and upper respiratory infections. About 90% of NT1 and 80% of NT2 LTE participants remained on treatment. Alixorexton continues in phase 3 Brilliance studies and the phase 2 Vibrance-3 IH study.
Alkermes (Nasdaq: ALKS) reported detailed phase 2 Vibrance-2 results for alixorexton in adults with narcolepsy type 2 (n=93). Once-daily alixorexton met dual primary endpoints at week 8, showing statistically significant, clinically meaningful improvements vs. placebo on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale.
Mean MWT latency rose from ~6 to up to ~16 minutes; most patients reported normal or mild sleepiness by week 8 and normal ESS scores by week 13. Exploratory fatigue and cognition measures improved, and alixorexton was generally well tolerated with no serious treatment-emergent adverse events. A global phase 3 Brilliance program in NT1 and NT2 is underway.
Alkermes (Nasdaq: ALKS) announced new orphan drug designations for alixorexton, an oral OX2R agonist for sleep disorders. The FDA granted ODD for idiopathic hypersomnia, and the European Commission granted ODD for narcolepsy.
Alixorexton, which previously received FDA Breakthrough Therapy designation for NT1, is in phase 3 Brilliance trials for NT1 and NT2 and the phase 2 Vibrance-3 study for IH, which Alkermes aims to complete this year. Orphan status in the U.S. and EU may provide tax credits, reduced fees, and up to seven to ten years of market exclusivity if approved.
Alkermes (Nasdaq:ALKS) will present 26 sleep-medicine abstracts at SLEEP 2026 in Baltimore, June 14–17, 2026. Highlights include detailed positive phase 2 Vibrance-2 data on investigational OX2R agonist alixorexton in narcolepsy type 2, and multiple studies of once-nightly LUMRYZ (sodium oxybate).
Presentations span phase 2 and phase 3 trial designs (Brilliance, REVITALYZ), real‑world LUMRYZ evidence (REFRESH), claims analyses on hypersomnolence disorders, and patient survey data on fatigue, cognition, and treatment preferences. LUMRYZ prescribing information emphasizes CNS depression, abuse/misuse risks, and REMS distribution requirements.
Alkermes (Nasdaq: ALKS) will join the Goldman Sachs 47th Annual Global Healthcare Conference, with a fireside chat on June 10, 2026 at 10:00 a.m. ET. A live webcast will be available via the Investors tab on Alkermes’ website and archived for 14 days.
Alkermes is a global biopharma company focused on neuroscience, with commercial products and late-stage pipeline candidates for addiction, psychiatric, sleep, and neurological disorders.
Alkermes (Nasdaq: ALKS) will present 11 posters at the American Society of Clinical Psychopharmacology Annual Meeting, May 26-29, 2026, in Miami.
Data span LYBALVI, ARISTADA, and investigational orexin 2 receptor agonists (alixorexton, ALKS 4510, ALKS 7290), covering schizophrenia, bipolar I disorder, narcolepsy, and idiopathic hypersomnia.
Alkermes (Nasdaq: ALKS) is presenting new clinical and real-world evidence for LYBALVI and ARISTADA at multiple spring 2026 psychiatry and health economics conferences. Key data cover LYBALVI’s impact on adherence, persistence, relapse proxies, hospitalizations and ER visits, including in young adults, plus long-acting injectable use in schizophrenia and sleep-disorder burden research.
The announcement also reiterates LYBALVI’s U.S. indications for adult schizophrenia and bipolar I disorder and highlights important safety information, including a boxed warning for dementia-related psychosis and contraindication with opioid use or acute opioid withdrawal.
Alkermes (Nasdaq: ALKS) reported positive topline results from the phase 3 REVITALYZ study of once-nightly LUMRYZ in adults with idiopathic hypersomnia. LUMRYZ met the primary ESS endpoint and key secondary PGI-C and IHSS endpoints (all p<0.0001) versus placebo, with a safety profile consistent with prior data. Alkermes plans to file an sNDA by end of 2026 but cannot market LUMRYZ for IH before March 1, 2028.
Alkermes (Nasdaq: ALKS) reported financial results for the quarter ended March 31, 2026 and provided financial expectations for full year 2026. The company will discuss results on a live conference call and webcast at 8:00 a.m. ET / 1:00 p.m. BST on May 5, 2026.
Investors can access the webcast and replay, and find the detailed earnings release and presentation, on Alkermes' investor relations website.